Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference
Nuvalent (Nasdaq: NUVL) announced that CEO James Porter, Ph.D. will present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nuvalent (Nasdaq: NUVL) announced that CEO James Porter, Ph.D. will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 9:00 a.m. PT in San Francisco.
A live webcast of the presentation will be available in the company's Investors section at www.nuvalent.com and the webcast will be archived for 30 days after the presentation.
Details
News Market Reaction – NUVL
On Dec 22, the day this news came out, NUVL closed 1.85% above the previous close.
Data tracked by StockTitan Argus for the Dec 22 session.
Key Figures
- Conference time
- 9:00 a.m. PT
- Presentation at 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
- Webcast archive
- 30 days
- Length of time conference webcast will remain available to investors
Historical Context
-
Appointment of experienced oncology executive Ron Squarer to Board of Directors.
-
Management participation in Piper Sandler healthcare conference fireside chat webcast.
-
Closing of public offering and full exercise of underwriters’ option by selling holders.
-
FDA acceptance of NDA for zidesamtinib in TKI pre-treated ROS1-positive NSCLC.
-
Pricing of large public offering of Class A common stock for ~$500M gross proceeds.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
kinase medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation.
About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302647193.html
SOURCE Nuvalent, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.